MetaCap

Matinas Biopharma (MTNB) vs China SXT Pharmaceuticals (SXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Matinas Biopharma is the larger company by market cap ($890,711 vs $273,955), about 3.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MTNB-71.12%SXTC-6.54%
+36%-34%-105%
Oct 7, 20261 yearNov 20, 2026
MTNB-72.13%SXTC+1678.75%
+2194%+1007%-180%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MTNB versus SXTC key metrics
MetricMTNBSXTC
Share price$0.7999$2.65
Market cap$890.71K$273.95K
1-day change-1.26%+2.12%
EPS (TTM)$-17.55$-73,040.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.14M
Revenue growth (YoY)—-34.63%
Net income (latest FY)$-10.35M$-6.21M
Gross margin—21.85%
Operating margin—-625.89%
Net margin—-545.24%
52-week high$14.63$8,376,000.00
52-week low$0.75$2.52
Distance from 52-week high-94.53%-100.00%
Average volume80.86K234.25K
Shares outstanding1.11M103.58K
Employees256
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Matinas Biopharma is about 3.3 times larger than China SXT Pharmaceuticals by market value ($890.71K vs $273.95K).

About Matinas Biopharma

MTNB stock →

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About China SXT Pharmaceuticals

SXTC stock →

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

MTNB vs SXTC FAQ

Which is bigger, Matinas Biopharma or China SXT Pharmaceuticals?

Matinas Biopharma (MTNB) is larger, with a market capitalization of $890.71K compared with $273.95K for China SXT Pharmaceuticals (SXTC).

Are Matinas Biopharma and China SXT Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons